Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 10 pages · English
• Transformational new results from an advanced AI-driven post-hoc analysis of Argenica’s Phase 2 trial, confirms statistically significant and clinically meaningful efficacy of ARG- 007 in severe acute ischaemic stroke patients — the patient population with the highest unmet need as they tend to have poorer outcomes post thrombectomy. • Given the strength of these results, together with previousl
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- AI Analysis Reveals Efficacy In Severe Stroke Patients
- Positive TNK Study Results Fulfil Key FDA Requirement
- ARG-007 Efficacious Dose Validated in New Preclinical Study
- Phase 2 Trial Promising Improvements in Functional Outcomes
- Topline Phase 2 Trial Results of ARG-007 in AIS Patients
Later from Argenica Therapeutics
- Successful Applicaton for EMA Paediatric Waiver
- Half Yearly Report and Accounts
- Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
- Presentations at European Stroke Organisation Conference
- Clinical Advisory Committee Established to Advance Phase 2b
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics